Harvest Partners SCF, LP Invests in Genstar Owned ConnectiveRx
Harvest Partners SCF, LP and Blackstone (NYSE:BX) Join as Minority Investors in Biopharmaceutical Services Market Leader
Genstar Capital, a leading private equity firm focused on investments in targeted segments of the financial services, healthcare, industrial, and software industries, today announced the recapitalization of its portfolio company ConnectiveRx, a leading provider of technology-enabled biopharmaceutical services. Genstar will continue as majority investor and will be joined by funds managed by Harvest Partners SCF, LP and funds managed by Blackstone Tactical Opportunities as minority investors.
The transaction provides ConnectiveRx with enhanced financial flexibility, allowing it to continue its product innovation-driven growth, while also enabling Genstar to realize a significant dividend for its shareholders. As part of the transaction, ConnectiveRx also completed a refinancing of its credit facility provided by KKR.
The company has more than doubled in size through organic and acquisition growth since Genstar initially invested in 2015. ConnectiveRx is a market-leading innovator in patient engagement and support, market access and adherence solutions for complex medications. The company partners with hundreds of biopharmaceutical manufacturers to simplify how patients get on and stay on prescribed therapy. To-date, the company has helped more than 84 million patients and 1.5 million healthcare providers, annually. Genstar invested in the company in 2015 and helped guide the creation of ConnectiveRx with Harry Totonis, a member of Genstar’s Strategic Advisory Board, and ConnectiveRx Chief Executive Officer.
This announcement appears as a matter of record only. This does not constitute an offer to sell or a solicitation of an offer to purchase an interest in any current or future HP SCF or Harvest Partners, LP fund.